Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
7486
¥ (incl. tax; regular price. Subscription price: ¥5,988)Wording
Definitive
How definitive the wording is.Announced details
CONC Eye Boost Injection
Applicable field (uses covered by this announcement)
At-home beauty care for loss of firmness around the eyes, dry dullness and dry fine lines
Launch date2 November 2026 (planned launch date)
What the company reported numerically
Quantitative Effects
Efficacy evaluation testing completed showing that dry fine lines are made less noticeable (specific numerical value: Not disclosed)
Offering price
¥7,486 (incl. tax) / ¥5,988 subscription price (incl. tax)
The company does not address Contract Value / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | CONC Eye Boost Injection |
| Offering price | ¥7,486 (incl. tax) / ¥5,988 subscription price (incl. tax) |
| Launch date | 2 November 2026 (planned launch date) |
| Applicable area | At-home beauty care for loss of firmness around the eyes, dry dullness and dry fine lines |
| Quantitative Effects | Efficacy evaluation testing completed showing that dry fine lines are made less noticeable (specific numerical value: Not disclosed) |
Items this document does not state (13)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The ingredients and technology were optimised for the eye area based on customer feedback on the existing series and the range of concerns specific to the eye area, including loss of firmness, dry dullness and dry fine lines.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.